Franzanne Vreeland

Phase I Trial of Taxotere: Five-Day Schedule

Richard Pazdur, Robert A. Newman, Beth Newman et al. · JNCI Journal of the National Cancer Institute · 1992 · 134 citations

The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth

Jana Divisová, Isere Kuiatse, ZaWaunyka Lazard et al. · Breast Cancer Research and Treatment · 2006 · 106 citations

Breast Oncology, Developmental Biology, Growth Hormone +8

Absolute bioavailability of letrozole in healthy postmenopausal women

A. Sioufi, N. Gauducheau, V. Pineau et al. · Biopharmaceutics & Drug Disposition · 1997 · 100 citations

Clinical Pharmacodynamic Effects of the Growth Hormone Receptor Antagonist Pegvisomant: Implications for Cancer Therapy

Donghua Yin, Franzanne Vreeland, Larry J. Schaaf et al. · Clinical Cancer Research · 2007 · 66 citations · Full text

Clinical experience with sorbinil—An aldose reductase inhibitor

Norman E. Pitts, Franzanne Vreeland, Gerald L. Shaw et al. · Metabolism · 1986 · 37 citations

Aldo-keto Reductase, Medicine, Drug Discovery +4